Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial ...

Inhibiting the AURKB enzyme significantly improves multiple measures of blood flow in rats with pulmonary arterial ...

New research could pave the way toward a new method of pulmonary arterial hypertension diagnosis and monitoring.

One example is a disease called phenylketonuria (PKU). It is caused by a change in the PAH gene. The PAH gene contains the information required to make the enzyme which breaks down phenylalanine ...

Although some cases of PAH have known causes, such as genetic factors, many cases have no identifiable underlying cause and are designated as idiopathic. Early diagnosis and treatment are critical ...

Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

The PKU-associated enzyme deficiency was determined biochemically in the 1950s—long before the PAH-encoding gene was mapped to human chromosome 12 and cloned in 1983. Specifically, Dr. Willard ...